Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Vybrin is a fibrin sealant designed for use as a surgical adhesive and hemostatic agent. It is a biological product typically composed of two primary components: human fibrinogen and human thrombin. When these components are mixed during application, they mimic the final stage of the natural blood coagulation cascade, converting fibrinogen into a fibrin clot. This fibrin matrix adheres to the wound surface, providing a physical barrier that promotes hemostasis and tissue sealing. Vybrin was developed to assist in controlling bleeding in surgical procedures where conventional techniques, such as sutures or cautery, are ineffective or impractical. It has been utilized in various surgical settings, including cardiovascular and general surgery, to prevent fluid leaks and support wound healing.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Vybrin.